Product information and disease descriptionProduct descriptionProduct information
Special populations
12 evidence topics · 11 sources
Older adults: pharmacokinetics in healthy men aged 65 years or older
“In part 4, there was no statistically significant difference between older adult and younger adult lorundrostat exposures (Table S4). The median T max value was earlier for older adult participants (1.0 h) vs. younger adult participants (1.5 h), and the mean t 1/2 value was slightly longer for older adult (11.4 h) than for younger adult (10.0 h) participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In parts 3 and 4, the change from baseline of PAC and serum cortisol concentrations at 24 h after a single 100‐mg dose of lorundrostat was similar in male and female participants, as well as in those aged 18–55 years and aged ≥65 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sex: pharmacokinetics in healthy women
“In part 3 of the study, after a single 100‐mg dose of lorundrostat, there was no statistically significant difference between lorundrostat exposure in females and males (Table S4). The median T max values were comparable for female participants (1.3 h) and male participants (1.5 h), and the mean t 1/2 value was slightly longer for females (12.4 h) than for males (10.0 h).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Age, sex, race, and body mass index: Launch-HTN subgroups
“The efficacy of lorundrostat for lowering BP was consistent across age, sex, race, BMI, and number of prescribed antihypertensive medications participants were taking (Figure 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Subgroup | Lorundrostat 50 mg, change in AOSBP at week 6 (mmHg) | Placebo, change in AOSBP at week 6 (mmHg) | Difference (90% CI) |
|---|---|---|---|
| Age ≥75 years | “-18.2” | “-6.6” | “-11.6 (-17.4, -5.8); p=0.0011” |
| Age 65 to 74 years | “-16.7” | “-9.8” | “-6.9 (-11.4, -2.4); p=0.0109” |
| Age <65 years | “-16.9” | “-7.6” | “-9.3 (-13.2, -5.4); p<0.0001” |
| Black or African American | “-15.1” | “-8.3” | “-6.7 (-11.6, -1.9); p<0.0222” |
| White | “-17.1” | “-8.0” | “-9.2 (-12.8, -5.6); p<0.0001” |
| Female | “-16.8” | “-7.4” | “-9.4 (-13.6, -5.3); p=0.0002” |
| Male | “-17.0” | “-8.2” | “-8.8 (-12.6, -5.1); p<0.0001” |
| BMI ≥30 kg/m2 | “-16.5” | “-6.9” | “-9.6 (-13.3, -5.8); p<0.0001” |
| BMI <30 kg/m2 | “-17.9” | “-9.5” | “-8.4 (-12.6, -4.3); p=0.0009” |
Race and ethnicity: first-in-human study population
Obesity: Target-HTN and Advance-HTN
“Most notably, participants with obesity demonstrated greater BP lowering in response to lorundrostat. Individuals with a BMI greater than 30 randomized to 50 mg once daily of lorundrostat demonstrated a −16.7 mm Hg (90% CI, −25.5 to −7.9 mm Hg) change in systolic AOBP compared with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Key secondary end point | Result |
|---|---|
| Relationship of BMI to blood pressure reduction at 4 weeks | “No clear relationship” |
Renal impairment: low urinary excretion of unchanged drug
Renal impairment: eGFR thresholds for enrollment
“The key exclusion criteria were an estimated glomerular filtration rate (eGFR) of less than 45 mL/min/1.73 m2, a serum potassium level of greater than 5.0 mmol/L at screening or greater than 4.8 mmol/L at randomization, and a serum sodium level of less than 135 mmol/L at screening.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Chronic kidney disease stages 1 to 3: Launch-HTN analysis
Chronic kidney disease with albuminuria: Explore-CKD
Hepatic impairment
No evidence found.